Navigation Links
Efficacy Advantages and Long-Term Cost Savings Will Help Optimize Reimbursement in the EU5 for Type 2 Diabetes Agents
Date:8/26/2013

BURLINGTON, Mass., Aug. 26, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that as the health technology assessment bar rises sharply across the EU5 (France, Germany, Italy, Spain and the United Kingdom), interviewed payers seek robust efficacy advantages over the right comparators and clear demonstration of potential for downstream cost savings in exchange for optimal reimbursement of type 2 diabetes therapies. As type 2 diabetes becomes increasingly prevalent in Western markets, the cost of related complications and comorbidities weighs heavily on tightening EU5 healthcare budgets. Payers report that novel agents that delay disease progression and show positive weight loss and cardiovascular outcomes data, ideally with detailed pharmacoeconomic analyses, will secure favorable market access conditions long term.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The new European Physician and Payer Forum report entitled Market Access Challenges Facing Newly Launched and Emerging Type 2 Diabetes Agents in the EU5: Physician Prescribing Perspectives and Payer Insights finds that at least three-quarters of surveyed EU5 endocrinologists, diabetologists and general practitioners (GPs) believe that, despite market crowding, unmet need remains for the DPP-IV inhibitor drug class, while at least two-thirds think likewise for the GLP-1 receptor agonists. Key unmet needs highlighted for the DPP-IV inhibitors include better reduction in HbA1c, and confirmation of disease-modifying effect, while—in addition to injection-free administration—positive cardiovascular outcomes data emerges as a primary preference for the GLP-1 analogues. Agents targeting these unmet needs should also help to address payer demands for downstream cost-savings, thus encouraging budget holders at all levels to think beyond the price tag as competition heightens among type 2 diabetes drug classes.    

However, the report also finds that as manufacturers strive for optimal pricing and reimbursement terms amid stringent HTA demands, they must be careful not to price themselves out of the market if they want to secure maximum uptake of their brands. Price must be carefully balanced with uptake potential for optimal return on investment.

"One quarter of surveyed GPs in Germany do not currently prescribe GLP-1 analogues to more than half of their eligible type 2 diabetes patients due to the constraints of their indicative prescribing budgets, while around two thirds of survey respondents in Spain report that their ability to prescribe DPP-IV inhibitors and GLP-1 analogues is at least somewhat impacted by recently increased patient copay," said Decision Resources Senior Director Janie Cox, Ph.D. "As the EU5 countries continue to feel the force of the economic crisis, industry is challenged with maximizing profitability at competitive rather than premium prices."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis
2. MedQIA unique CAD algorithm for Quantitation of lung involvement in diffuse lung disease used as treatment efficacy end point in study to be reported at the ERS Annual Conference in Vienna, Austria: September 1-5, 2012
3. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
4. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
5. Optimization of Comparative Efficacy Trials
6. JAMA Study Demonstrates Efficacy of Life Technologies Lung Cancer Test in Detecting Early Metastases, Supports Screening for Lung Cancer
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
9. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
10. Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab Based on Efficacy Results
11. Data Demonstrating the Safety and Efficacy of Chimerixs Antiviral CMX001 Presented at BMT Tandem Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... , Mar 01, 2017 Research and Markets has ... Diagnostics Tests for Cancer & Infectious Diseases" report to their offering. ... Did you know? ... Marketing, U.S. Breast/Colon at Genomic Health, Inc.. - Beijing Wantai Biological ... for the production of infectious diseases diagnostics in China ...
(Date:3/1/2017)... March 1, 2017  The world,s largest pharmaceutical event ... May 16 - 18, 2017. Utilizing the strength ... the leading fine and specialty chemical event, CPhI North ... educational programs: CPhI Connect, focusing on pharmaceuticals, and InformEx ... Powered by the expertise of the American Chemical ...
(Date:3/1/2017)... 2017  The Pharmaceutical Care Management Association (PCMA) issued ... to advance the nomination of Seema Verma ... Administrator: "The popular Medicare Part D ... health care. By offering an abundance of competing plan ... like pharmacy networks and home delivery, the program is ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... March 01, 2017 , ... Cotton Incorporated and PurThread Technologies, ... knit and woven fabrics. , Retail brands and consumers alike continue to ... of cotton. Cotton Incorporated has developed cotton-rich fabrics with PurThread that offer ...
(Date:3/1/2017)... ... March 01, 2017 , ... Grund® America is ... and Bath Rugs launching at the March 2017 International Housewares Show in Chicago (Grund ... which are made with the highest quality,100% OEKO-TEX and GOTS Organic Cotton material. ...
(Date:3/1/2017)... ... 2017 , ... NYC based Integrated practice Living Well Medical, a long time ... of Orthopaedic Surgeon Dr. Donald E. Heitman. Dr. Heitman is a native ... Bachelor of Science degree in biology. He then obtained his medical degree from New ...
(Date:3/1/2017)... ... 2017 , ... “McFarnia”: a suspenseful tale of a father who vanishes without ... mysterious disappearance. “McFarnia” is the creation of published author Tony Pierzchala, a former Army ... as a Chaplain with Transport for Christ at a truck stop in the Greensboro ...
(Date:3/1/2017)... ... 01, 2017 , ... “Our Pure Need of Obedience to the Law of God”: a message ... Pure Need of Obedience to the Law of God” is the creation of published author ... and his wife, Anika, and children have since dedicated their lives to spreading God’s word ...
Breaking Medicine News(10 mins):